Korean Authorities Mull New Steps, Probe Over Olmutinib Events
Executive Summary
Additional safety measures including a possible sales suspension are to be discussed by a review committee in South Korea on Oct. 4 that will help decide the fate of Hanmi’s EGFR inhibitor olmutinib. Financial authorities in the country are also launching a probe into the timing of the disclosure of several cases of serious adverse events with the drug.
You may also be interested in...
Prosecutors Raid Hanmi HQ As Olmutinib Probe Gets Serious
Following the start of a probe by financial authorities earlier this month into suspicions Hanmi may have leaked undisclosed information relating to the return of rights to its cancer drug olmutinib, prosecutors have raided the headquarters of the South Korean pharma to get to the bottom of the affair.
Samsung BioLogics IPO May Set Tone For Korean Biopharma Investors
Samsung BioLogics has set out plans for one of the biggest ever IPOs in South Korea that could help reignite investor sentiment battered by recent events surrounding Hanmi.
Korea To Limit Olmutinib Usage, Monitor All Patients
After distributing safety letters on several cases of serious adverse skin reactions that occurred during the clinical development of Hanmi’s olmutinib, South Korean authorities have decided to limit the EGFR inhibitor to consenting patients and are closely monitoring its use.